10.15 | 7.15 Opportunities for Liquid Biopsy Across the Continuum of Care
Time: 10:15 am
day: Day One
Details:
- With the successful clinical adoption of LBx in late stage cancer, attention is now turning to opportunities earlier in the patient journey
- Earlier stage cancers require integration of several biomarkers to deliver appropriate sensitivity
- Progress is being made to generate the evidence to support clinical adoption, but regulatory and reimbursement hurdles must also be overcome
